Tirzepatide's Role in Postmenopausal HR+ Breast Cancer Survivors
This study will explore whether tirzepatide is a practical and acceptable treatment for postmenopausal females with a history of hormone receptor-positive breast cancer and obesity. The investigators aim to understand whether participants are willing and able to take this medication once weekly for 6 months and whether it may help improve weight and overall health. There will be monthly check-ins to monitor progress and safety. At the beginning and end of the study, participants will undergo body composition assessments, blood tests and a stool sample will be collected, and surveys will be completed.
• Biologically female
• Age ≥ 18
• Obesity as defined by current BMI ≥ 30 kg/m²
• Postmenopausal as defined by one or more of the following
‣ Age ≥60 years
⁃ Age \<60 years with amenorrhea for ≥ 1 year
⁃ Documented bilateral surgical oophorectomy
⁃ Chemical menopause with the addition of LHRH agonists at least 12 weeks prior to enrolment, and plan to remain on LHRH agonists throughout the trial
• HR+ (ER and/or PR) stage 0-III breast cancer
• Completed curative treatment (surgery, chemotherapy, radiotherapy) at least 12 weeks prior to enrolment
• Insurance approval for tirzepatide or willing to pay out of pocket
• Willing to provide informed consent and comply with study procedures